



InterQual Anonymous Review

Conduct interactive medical reviews without compromising PHI

InterQual® Anonymous Review is a flexible, Software-as-a-Service (SaaS) solution that enables you to conduct medical reviews while safeguarding sensitive PHI. Our solution drives time and cost efficiencies and offers numerous benefits, including:

- User interface complements case managers' workflow and provides immediate access to InterQual criteria from any browser.
- The most recent, evidenced-based clinical criteria are delivered automatically as they are released by our clinical development team – no need for you to install or validate. You can choose when users see the new versions and configure which criteria subsets appear, including criteria created with InterQual Customize.
- Users perform the InterQual review without having to specify patient data. Case managers can add notes about the patient, treatment, and/or diagnosis within the criteria points to defend the clinical decision, then copy/paste this content into an internal document management system or create a PDF to save/print. (For organizations with disparate systems, this feature addresses interoperability challenges.) **Sensitive PHI is neither saved nor transferred between disparate systems, helping you to comply with strict government DICAP requirements.**
- Since this is a SaaS solution, it is fast and easy to implement, with an average time of 3 business days required.

Step Up To Greater Functionality

- Integrated
 - Medical Review Service
- Interactive
 - Anonymous Review
- Reference
 - Online
 - Transparency
- Access (included with your license)
 - View
 - Mobile

MENU

INTERQUAL DEMO

LOCK SCREEN

HELP

Medical Review COPD

CHANGE SUBSET

CLINICAL REFERENCE

INTERMEDIATE MET

EPISODE DAY 1

CLEAR ALL

EXPAND ALL

COLLAPSE ALL

COMMENTS 0

BENCHMARK LOS

(Symptom or finding within 24h) (Excludes PO medications unless noted)

Episode Day 1, One:

OBSERVATION, All:

ACUTE, All:

INTERMEDIATE, All:

Dyspnea unresolved

Short-acting beta-agonist ≥ 3 doses, \geq One:

Administered in the ED

Administered in medical practitioner's office

Finding, \geq One:

Arterial Po_2 40–55 mmHg(5.3–7.3 kPa) and pH 7.50–7.55

Arterial Pco_2 55–59 mmHg(7.3–7.9 kPa) and pH 7.25–7.30

Central cyanosis, new onset

Central cyanosis, worsening

ADMISSION CONSIDERATIONS

EXPECTED PROGRESS

CARE FACILITATION

COPD: Admission considerations

Prior to initiating a review, obtain documentation of the following information in order to apply the criteria or provide additional information for a possible secondary review:

Clinical findings following at least 3 doses of a short acting beta agonist, including:

- Work of breathing
- O2 saturation
- Arterial or venous Po_2
- Arterial or venous Pco_2

Any active comorbid conditions or risk factors that may impact the decision to admit, such as:

PREVIOUS

MEDICAL REVIEW COMPLETED

Our user-friendly interface enables you to conduct interactive medical reviews while safeguarding sensitive PHI.

Minimum Requirements

- Google Chrome™, Microsoft®Edge, and Mozilla Firefox™ browsers are supported
- A PDF reader is required to view InterQual Clinical Reference materials
- Recommended screen resolution of 1024 x 768 pixels or higher
- Reliable, high-speed internet connection
- Single sign-on is an available option: For SAML 2.0 SSO, a class 2 or greater certificate issued by a public Certificate Authority is required

* Google Chrome™ is a trademark and brand of Google LLC. Microsoft® Edge is a registered trademark of the Microsoft Corporation. Firefox™ is a trademark of the Mozilla Foundation.

optum.com

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2023 Optum, Inc. All rights reserved. WF10379682 04/23